In studies using CD19-positive pre-B cell ALL and mixed lineage leukemia (MLL) xenografts, the administration of SAR3419 delayed disease progression, even in chemotherapy-resistant xenograft models [18]. Here, CD19 is linked to acute lymphoblastic leukemia.